Paul Volberding, MD

Professor Emeritus

I was trained in Medical Oncology but became involved in the early AIDS epidemic in San Francisco based at San Francisco General Hospital. I have worked in clinical trials in HIV-related malignancies but primarily in the development of antiretroviral therapy. I was the PI and co-director with Warner Greene of the NIAID-funded UCSF-Gladstone Center for AIDS Research supporting the large community of HIV investigators in San Francisco. CFAR provides core services, pilot grants to early career stage investigators and supports a comprehensive mentorship program. In the Clinical and Translational Sciences Institute I served as a member of the Board of Directors and formerly directed the Global Health Program. I stepped down as the Chief of the Medical Service at the San Francisco VA Medical Center in 2012 to become the Director of the UCSF AIDS Research Institute. The ARI is the comprehensive University organization that links all HIV/AIDS research programs and is the central focus for communications, media relations and philanthropic support for this internationally recognized response to the HIV epidemic. In 2015, the ARI became the administrative home for a unique initiative to cure HIV infection funded by amfAR, the Foundation for AIDS Research. I served until recently as the Director of the amfAR Institute for HIV Cure, working with leading scientists at UCSF, the Gladstone Institute for Virology and Immunology, and the Vitalant (formerly the Blood Systems) Research Institute. I also served as the Associate Chair of the UCSF Department of Medicine for Global Health. My clinical appointment is at the VA as a retired volunteer physician where I maintain an active HIV outpatient practice. I am the Clinical Editor in Chief of the Journal of the Acquired Immunodeficiency Syndromes and served as the Chair of the Scientific Advisory Board of the Accordia Global AIDS Foundation and the Infectious Diseases Institute at Makerere University in Kampala Uganda. I was a board member of the Pangaea Global AIDS Foundation. I am an active member of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academy of Sciences and am the founder and Board Chair of the International Antiviral Society-USA. On Twitter I am @pvolberding.
Education
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
M.D., 1975 - , University of Minnesota
A.B., 1971 - , University of Chicago
Honors and Awards
  • Master, American College of Physicians, 2015
  • Member, Institute of Medicine, 1999
Websites
Publications

  1. Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center. 2023. PMID: 38060289


  2. Esmaeilzadeh E, Etemad B, Lavine CL, Garneau L, Li Y, Regan J, Wong C, Sharaf R, Connick E, Volberding P, Sagar M, Seaman MS, Li JZ. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption. 2023. PMID: 37163616


  3. Etemad B, Sun X, Li Y, Melberg M, Moisi D, Gottlieb R, Ahmed H, Aga E, Bosch RJ, Acosta EP, Yuki Y, Martin MP, Carrington M, Gandhi RT, Jacobson JM, Volberding P, Connick E, Mitsuyasu R, Frank I, Saag M, Eron JJ, Skiest D, Margolis DM, Havlir D, Schooley RT, Lederman MM, Yu XG, Li JZ. HIV post-treatment controllers have distinct immunological and virological features. 2023. PMID: 36877848


  4. Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, Etemad B, Connick E, Jacobson JM, Margolis DM, Skiest D, Volberding P, Hecht F, Deeks S, Wong JK, Li JZ, Yukl SA. Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. 2022. PMID: 36541802


  5. Malekinejad M, Jimsheleishvili S, Barker EK, Hutchinson AB, Shrestha RK, Volberding P, Kahn JG. Sexual Practice Changes Post-HIV Diagnosis Among Men Who Have Sex with Men in the United States: A Systematic Review and Meta-analysis. 2022. PMID: 35829969


  6. Lederman MM, Flier JS, Hale P, Haase AT, Powderly W, Reiss P, Silvestri G, Sekaly RP, Paiardini M, Weissman D, Kuritzkes DR, Calabrese LH, Agre P, Reyes-Teran G, Landay AL, Lewin S, Richman DD, Volberding P, Hunt PW, Schechter M. Is France Once Again Looking for a Scapegoat? 2021. PMID: 35097250


  7. Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest DJ, Margolis D, Sneller MC, Little SJ, Gulick RM, Mellors JW, Gandhi RT, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Hecht FM, Li JZ, CHAMP study team. Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. 2021. PMID: 34127579


  8. Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, Horberg MA, Volberding P, Weisner C, Silverberg MJ. The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system. 2021. PMID: 33429295


  9. Malekinejad M, Blodgett J, Horvath H, Parriott A, Hutchinson AB, Shrestha RK, McCabe D, Volberding P, Kahn JG. Change in Condom Use in Populations Newly Aware of HIV Diagnosis in the United States and Canada: A Systematic Review and Meta-Analysis. 2021. PMID: 33389321


  10. Satre DD, Parthasarathy S, Silverberg MJ, Horberg M, Young-Wolff KC, Williams EC, Volberding P, Campbell CI. Health care utilization and HIV clinical outcomes among newly enrolled patients following Affordable Care Act implementation in a California integrated health system: a longitudinal study. 2020. PMID: 33176760


  11. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, Smith DM, Benson CA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. 2020. PMID: 33052386


  13. Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. 2020. PMID: 32198297


  16. Satre DD, Anderson AN, Leibowitz AS, Levine-Hall T, Slome S, Flamm J, Hare CB, McNeely J, Weisner CM, Horberg M, Volberding P, Silverberg MJ. Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the promoting access to care engagement (PACE) trial. 2019. PMID: 31446142


  18. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, Horberg M, Volberding P, Silverberg MJ. Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial. 2019. PMID: 31187344


  20. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. 2018. PMID: 30085241


  21. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. 2018. PMID: 30024859


  22. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. 2018. PMID: 30043070


  23. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. 2018. PMID: 29593048


  24. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. 2017. PMID: 28208122


  25. Malekinejad M, Parriott A, Blodgett JC, Horvath H, Shrestha RK, Hutchinson AB, Volberding P, Kahn JG. Effectiveness of community-based condom distribution interventions to prevent HIV in the United States: A systematic review and meta-analysis. 2017. PMID: 28771484


  26. Volberding PA. How to Survive a Plague: The Next Great HIV/AIDS History. 2017. PMID: 28384806


  28. Volberding P, Blattner WA. JAIDS: Transitions, Evolution, and Impact. 2017. PMID: 27926666


  31. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. 2016. PMID: 27576871


  32. Meffert SM, Shome S, Neylan TC, Musalo K, Fineberg HV, Cooke MM, Volberding PA, Goosby EP. Health impact of human rights testimony: harming the most vulnerable? Volume 1 of Issue 1. 2016. PMID: 28588904


  33. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. 2016. PMID: 27404187


  35. Tang W, Han L, Best J, Zhang Y, Mollan K, Kim J, Liu F, Hudgens M, Bayus B, Terris-Prestholt F, Galler S, Yang L, Peeling R, Volberding P, Ma B, Xu H, Yang B, Huang S, Fenton K, Wei C, Tucker JD. Crowdsourcing HIV Test Promotion Videos: A Noninferiority Randomized Controlled Trial in China. 2016. PMID: 27129465


  36. Shearer DW, Volberding PA, Schemitsch EH, Cook GE, Slobogean GP, Morshed S. Building Networks for Global Clinical Research: The Basics. 2015. PMID: 26584260


  37. Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, Volberding P, Tucker JD. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. 2015. PMID: 25427547


  38. Lambdin BH, Cheng B, Peter T, Mbwambo J, Apollo T, Dunbar M, Udoh IC, Cattamanchi A, Geng EH, Volberding P. Implementing Implementation Science: An Approach for HIV Prevention, Care and Treatment Programs. 2015. PMID: 25986374


  40. Tucker JD, Volberding PA, Margolis DM, Rennie S, Barré-Sinoussi F. Words matter: Discussing research towards an HIV cure in research and clinical contexts. 2014. PMID: 25314254


  41. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. 2014. PMID: 25038359


  42. Volberding P. HIV cure: the target is clearer but not yet close. 2014. PMID: 24424733


  43. Volberding PA. Solving the mystery of JAIDS. 2013. PMID: 23722609


  45. El-Sadr WM, Morrison JS, Quinn T, Volberding P. A chronicle of hope and promise: the world as it was, as it is, and as it can be. 2012. PMID: 22797739


  46. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. 2012. PMID: 22820792


  47. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. 2012. PMID: 22688010


  49. Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB. Clinician attitudes about commercial support of continuing medical education: results of a detailed survey. 2011. PMID: 21555662


  50. Martin J, Volberding P. HIV and premature aging: A field still in its infancy. 2010. PMID: 20921548


  51. Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding PA, Demeter LM. Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. 2010. PMID: 20733405


  52. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. 2010. PMID: 20639566


  53. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. 2010. PMID: 20609987


  54. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. 2010. PMID: 20520594


  55. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. 2010. PMID: 20100969


  56. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. 2009. PMID: 19696651


  58. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. 2008. PMID: 18677028


  59. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. 2007. PMID: 18190326


  60. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. 2007. PMID: 17942954


  61. Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, Volberding PA. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. 2007. PMID: 17443478


  62. Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). 2007. PMID: 17091020


  63. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. 2006. PMID: 16905788


  64. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. 2006. PMID: 17016878


  65. Volberding PA. The New York case: lessons being learned. 2005. PMID: 15845950


  66. Behler C, Shade S, Gregory K, Abrams D, Volberding P. Anemia and HIV in the antiretroviral era: potential significance of testosterone. Volume 21 of Issue 3. 2005. PMID: 15795525


  67. Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. 2004. PMID: 15591945


  69. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. 2004. PMID: 15282352


  70. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. 2004. PMID: 15249575


  71. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. 2004. PMID: 15156485


  74. Volberding PA. HIV therapy in 2003: consensus and controversy. 2003. PMID: 12870525


  75. Volberding PA, Murphy RL, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie PF, Di Lorenzo G, Fantoni M, Filiced G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Stein JH, Torre D, Vittecoq D. The pavia consensus statement. 2003. PMID: 12870544


  76. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. 2003. PMID: 12646792


  77. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. 2003. PMID: 14633787


  80. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. 2002. PMID: 12095387


  81. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? 2002. PMID: 12095390


  82. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. 2002. PMID: 12167274


  85. Volberding PA. Who cares for AIDS? 2002. PMID: 11903780